WaveMan
WaveMan · Company
UPB · Upstream Bio, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

UPB Upstream Bio (UPB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0002022626
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
102
13F, latest reported quarter

What the filings say about UPB

Insiders, 180 days
-$58.2K net sold
5 sellers · 0% of sales under a 10b5-1 plan

Upstream Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Upstream Bio, Inc. insiders sold a net $58.2K of stock across 20 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
GRAY MICHAEL
CFO and COO
SELL
2026-09-17 SECtraded 2026-09-16
853
$4.7K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 3.1% of the 27,942 shares held after it.
  • 4 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and COO GRAY MICHAEL sold about $4.7K of UPB on Sep 16, 2026; 4 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Ambrose Allison
General Counsel
SELL
2026-09-17 SECtraded 2026-09-16
485
$2.7K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 3.1% of the 15,563 shares held after it.
  • 4 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Ambrose Allison sold about $2.7K of UPB on Sep 16, 2026; 4 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Deykin Aaron
Chief Medical Officer
SELL
2026-09-17 SECtraded 2026-09-16
895
$4.9K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 2.8% of the 32,302 shares held after it.
  • 4 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Deykin Aaron sold about $4.9K of UPB on Sep 16, 2026; 4 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Sutherland Everett Rand
Chief Executive Officer
SELL
2026-09-17 SECtraded 2026-09-16
2,095
$11.5K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 3.0% of the 68,717 shares held after it.
  • 4 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Sutherland Everett Rand sold about $11.5K of UPB on Sep 16, 2026; 4 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
Houghton Adam
Chief Business Officer
SELL
2026-09-17 SECtraded 2026-09-16
700
$3.8K
-48.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 3.1% of the 22,901 shares held after it.
  • 4 other insiders sold within 30 days.
  • 102 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Business Officer Houghton Adam sold about $3.8K of UPB on Sep 16, 2026; 4 other insiders sold within 30 days and 102 funds added in the latest 13F quarter.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 15 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$58.2K over 180 days
-$27.6K over 90 days
more than 57% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
102 funds bought in last quarter
more than 69% of Pharma & Biotech
Revenue
+20.4% year over year
more than 67% of Pharma & Biotech
Margin
-5026.0% net margin
below 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.6% of the float short (float per yahoo 2026-10-26) · 7.7 days to cover · settled 2026-09-30
more than 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch UPB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-87.6%12M
-88%-43%+2%+47%2025-102025-122026-022026-042026-062026-082026-10 2026-03-16 · Sutherland Everett Rand sold $19.4K2026-06-16 · Sutherland Everett Rand sold $12.8K2026-09-16 · Sutherland Everett Rand sold $11.5K2026-03-16 · Deykin Aaron sold $8.3K2026-03-16 · GRAY MICHAEL sold $7.9K2026-03-16 · Houghton Adam sold $6.5K2026-06-16 · Deykin Aaron sold $5.5K2026-06-16 · GRAY MICHAEL sold $5.2K2026-09-16 · Deykin Aaron sold $4.9K2026-09-16 · GRAY MICHAEL sold $4.7K2026-03-16 · Ambrose Allison sold $4.4K2026-06-16 · Houghton Adam sold $4.3K2026-09-16 · Houghton Adam sold $3.8K2026-06-16 · Ambrose Allison sold $2.9K2026-09-16 · Ambrose Allison sold $2.7K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns UPB: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
8,162,897 sh
$56.5M
ORBIMED ADVISORS LLC
5,693,589 sh
$39.4M
NORGES BANK
3,768,619 sh
$26.1M
BlackRock, Inc.
3,753,358 sh
$26.0M
Decheng Capital LLC
2,724,868 sh
$18.9M

Congress trades in UPB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

UPB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

UPB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$321.5K position · as of 2026-07-31
0.7%
Simplify Propel Opportunities ETF
$429.8K position · as of 2026-06-30
0.6%
Fidelity Disruptive Medicine ETF
$208.2K position · as of 2026-05-31
0.5%
ALPS Medical Breakthroughs ETF
$465.6K position · as of 2026-05-31
0.3%
Fidelity Advisor Biotechnology Fund
$4.4M position · as of 2026-07-31
0.2%
VANGUARD MARKET NEUTRAL FUND
$1.2M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
4
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $58.2K sold by insiders over 180 days, 102 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

UPB financials

Revenue growth
+20.4%
XBRL, annual
Net margin
-5026.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-4,956%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-46.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-44.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$2.9M$2.4M$2.4M
Operating income-$160.4M-$77.8M-$40.1M
Net income-$143.4M-$62.8M-$20.5M
EPS (diluted)-2.66-5.58-12.95
Operating cash flow-$133.3M-$59.2M-$37.9M
Cash$101.6M$325.9M$25.8M
SEC XBRL, fiscal years, as known on 2026-10-27

UPB Stock Sonar score 5/7 axes

Find similar shapesCompare

UPB ranks highest on institutional and government (69th percentile) and growth (67th), and lowest on insider conviction (28th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
52
Inputs
  • Return on equity-46.0% · 57 pct, sector of 545
  • Return on assets-44.6% · 48 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.9% · 50 pct, sector of 576
Growth
67
Inputs
  • Revenue growth, YoY+20.4% · 67 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$58K · 56 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
69
Inputs
  • Funds adding, latest quarter102 · 69 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
52
Inputs
  • Short interest, % of float+10.6% · 38 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+7.6% · 67 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

UPB filings, in plain words

Are Upstream Bio insiders buying or selling UPB?

In the 180 days to 2026-10-27, Upstream Bio insiders were net sellers, a net $58.2K across purchases and sales reported on Form 4, by 5 sellers.

Read the full summary

In the 180 days to 2026-10-27, Upstream Bio insiders were net sellers of UPB, a net $58.2K across purchases and sales reported on Form 4 by 5 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies